Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Ensysce Biosciences Q4 EPS $(1.13) Misses $(0.87) Estimate, Sales $515.03K Beat $390.00K Estimate

Author: Benzinga Newsdesk | March 15, 2024 08:06am

Ensysce Biosciences (NASDAQ:ENSC) reported quarterly losses of $(1.13) per share which missed the analyst consensus estimate of $(0.87) by 29.89 percent. This is a 93.8 percent increase over losses of $(18.24) per share from the same period last year. The company reported quarterly sales of $515.03 thousand which beat the analyst consensus estimate of $390.00 thousand by 32.06 percent. This is a 64.06 percent decrease over sales of $1.43 million the same period last year.

Posted In: ENSC


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist